Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Liver Transpl ; 15(12): 1709-17, 2009 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-19938119

RESUMEN

University of Wisconsin solution (UWS) is the gold standard for graft preservation. Celsior solution (CS) is a new solution not as yet widely used in liver grafts. The aim of this study was to compare the liver function of transplanted grafts stored in these 2 preservation solutions. The primary endpoints were the rates of primary nonfunction (PNF) and primary dysfunction (PDF). We performed a prospective and pseudorandomized study that included 196 patients (representing 104 and 92 livers preserved in UWS and CS, respectively) at La Fe University Hospital (Valencia, Spain) between March 2003 and May 2005. PNF and PDF rates, liver function laboratory parameters, postoperative bleeding, vascular and biliary complications, and patient and graft survival at 3 years were compared for the 2 groups. The 2 groups were similar in terms of donor variables, recipient variables, and surgical techniques. The PNF rates were 2.2% and 1.9% in the CS and UWS groups, respectively (P = not significant), and the PDF rates were 15.2% and 15.5% in the CS and UWS groups, respectively (P = not significant). There were no significant differences in the laboratory parameters for the 2 groups, except for alanine aminotransferase levels in month 3, which were lower in the CS group (P = 0.01). No significant differences were observed in terms of complications. Three-year patient and graft survival rates were as follows for years 1, 2, and 3: 83%, 80%, and 76% (patient) and 80%, 77%, and 73% (graft) for the UWS group and 83%, 77%, and 70% (patient) and 81%, 73%, and 67% (graft) for the CS group (P = not significant). In conclusion, this study shows that CS is as effective as UWS in liver preservation.


Asunto(s)
Trasplante de Hígado , Hígado/efectos de los fármacos , Soluciones Preservantes de Órganos/uso terapéutico , Preservación de Órganos/métodos , Disfunción Primaria del Injerto/prevención & control , Adenosina/uso terapéutico , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Alopurinol/uso terapéutico , Enfermedades de las Vías Biliares/etiología , Disacáridos/efectos adversos , Disacáridos/uso terapéutico , Electrólitos/efectos adversos , Electrólitos/uso terapéutico , Femenino , Glutamatos/efectos adversos , Glutamatos/uso terapéutico , Glutatión/efectos adversos , Glutatión/uso terapéutico , Supervivencia de Injerto/efectos de los fármacos , Histidina/efectos adversos , Histidina/uso terapéutico , Humanos , Insulina/uso terapéutico , Hígado/cirugía , Pruebas de Función Hepática , Trasplante de Hígado/efectos adversos , Trasplante de Hígado/mortalidad , Masculino , Manitol/efectos adversos , Manitol/uso terapéutico , Persona de Mediana Edad , Proyectos Piloto , Hemorragia Posoperatoria/etiología , Disfunción Primaria del Injerto/etiología , Estudios Prospectivos , Rafinosa/uso terapéutico , Factores de Tiempo , Trasplante Homólogo , Enfermedades Vasculares/etiología , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA